However, Celgene is a company he is had some experience with cancer drug combinations itself: the FDA recently approved the company???s application to market Pomalyst (pomalidomide) for relapsed and refractory multiple myeloma (MM) patients who did not respond to treatment within 60 days of completion of their last therapy involving two other drugs, one of which is another Celgene drug for MM, th